Interestingly, recent studies show that LXR agonist inhibits tumor growth and progression of LNCaP prostate cancer cells (Chuu et al. 2006; Fukuchi et al. 2004b) and androgenic inhibition of ABCA1 is involved in the regulation of prostate cancer growth (Fukuchi et al. 2004a). This evidence concerns the gene ABCA1 and prostate cancer.